Audrey Joannes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Audrey Joannes has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Béatrice Nawrocki-Raby
Université de Reims Champagne-Ardenne, INSERM, P3Cell, UMR-S 1250, Reims, France
10 shared publications - Christine Gilles
GIGA-Cancer, Laboratory of Tumor and Development Biology, University of Liège, Liège, Belgium
10 shared publications Claire Kileztky
10 shared publications- Laurent Duca
Extracellular Matrix and Cell Dynamics (MEDyC) CNRS UMR7369, University Reims Champagne‐Ardenne France
10 shared publications - Myriam Polette
Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, 51092 Reims, France
10 shared publications Philippe Birembaut
10 shared publications
Latest Publications
- 1 December 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (6) , L818-L830
Identification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis
FGFR4 has been reported to have antifibrotic effects in the liver. We aimed to determine the involvement of FGFR4 during IPF. Our data suggest that FGFR4 exerts profibrotic properties by enhancing TGF-β signaling in vitro. However, the inhibition of FGFR4 is not sufficient to prevent the development of pulmonary fibrosis in vivo. To our knowledge, this is the first study to assess the profibrotic action of FGFR4 during pulmonary fibrosis.
- 1 December 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (6) , L818-L830
Identification of FGFR4 as a regulator of myofibroblast differentiation in pulmonary fibrosis
FGFR4 has been reported to have antifibrotic effects in the liver. We aimed to determine the involvement of FGFR4 during IPF. Our data suggest that FGFR4 exerts profibrotic properties by enhancing TGF-β signaling in vitro. However, the inhibition of FGFR4 is not sufficient to prevent the development of pulmonary fibrosis in vivo. To our knowledge, this is the first study to assess the profibrotic action of FGFR4 during pulmonary fibrosis.
- 5 January 2024
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 125, 109558
Antifibrotic effects of vitamin D3 on human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
- 5 January 2024
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 125, 109558
Antifibrotic effects of vitamin D3 on human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
- Open Access
- 30 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (2)
ERS International Congress 2023: highlights from the Basic and Translational Sciences Assembly
Early career members of Assembly 3 (Basic and Translational Sciences) of the European Respiratory Society (ERS) summarise the key messages discussed during six selected sessions that took place at the ERS International Congress 2023 in Milan, Italy. Aligned with the theme of the congress, the first session covered is “Micro- and macro-environments and respiratory health”, which is followed by a summary of the “Scientific year in review” session. Next, recent advances in experimental methodologies and new technologies are discussed from the “Tissue modelling and remodelling” session and a summary provided of the translational science session, “What did you always want to know about omics analyses for clinical practice?”, which was organised as part of the ERS Translational Science initiative's aims. The “Lost in translation: new insights into cell-to-cell crosstalk in lung disease” session highlighted how next-generation sequencing can be integrated with laboratory methods, and a final summary of studies is presented from the “From the transcriptome landscape to innovative preclinical models in lung diseases” session, which links the transcriptome landscape with innovative preclinical models. The wide range of topics covered in the selected sessions and the high quality of the research discussed demonstrate the strength of the basic and translational science being presented at the international respiratory conference organised by the ERS.
- 30 November 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (2)
Open AccessERS International Congress 2023: highlights from the Basic and Translational Sciences Assembly
Early career members of Assembly 3 (Basic and Translational Sciences) of the European Respiratory Society (ERS) summarise the key messages discussed during six selected sessions that took place at the ERS International Congress 2023 in Milan, Italy. Aligned with the theme of the congress, the first session covered is “Micro- and macro-environments and respiratory health”, which is followed by a summary of the “Scientific year in review” session. Next, recent advances in experimental methodologies and new technologies are discussed from the “Tissue modelling and remodelling” session and a summary provided of the translational science session, “What did you always want to know about omics analyses for clinical practice?”, which was organised as part of the ERS Translational Science initiative's aims. The “Lost in translation: new insights into cell-to-cell crosstalk in lung disease” session highlighted how next-generation sequencing can be integrated with laboratory methods, and a final summary of studies is presented from the “From the transcriptome landscape to innovative preclinical models in lung diseases” session, which links the transcriptome landscape with innovative preclinical models. The wide range of topics covered in the selected sessions and the high quality of the research discussed demonstrate the strength of the basic and translational science being presented at the international respiratory conference organised by the ERS.
- 15 November 2023
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 83, 102267
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- 15 November 2023
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 83, 102267
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)